Abstract 365P
Background
Nasopharyngeal carcinoma (NPC) is one of the most common malignancies in Malaysia and the incidence rate is high in the state of Sabah. Patients in Sabah are known to have limitations to access the healthcare services in the state. The purpose of this study is to examine the survival results, failure patterns, and compliance rate of patients with nasopharyngeal cancer who received radical radiotherapy with or without chemotherapy in Sabah.
Methods
A retrospective analysis was performed on patients diagnosed with stage I-IVA (AJCC staging 8th edition) NPC and treated with radiotherapy between the years of 2017-2019 in Sabah Women and Children's Hospital. The Kaplan-Meier method was used for survival analysis and differences in survival according to AJCC stage was compared using the log-rank test.
Results
A total of 140 patients were treated during this period. Most of them presented late at diagnosis, stage III (39%) and stage IVA (40%). Majority of them were treated with IMRT technique (85%). The compliance rate to radiotherapy was 96%. The 3-year overall survival (OS), disease-free-survival (DFS), local-failure-free survival (LFFS), regional-failure-free survival (RFFS), distant-failure-free survival (DFFS), of NPC patients in this study are 70%, 61%, 83%, 84%, and 67% respectively. The LFFS was significantly different between T stages (P value = 0.003) and T4 stage had the lowest rate of 3-year LFFS (65%). The RFFS was significantly different between N stages (P value = 0.013) and the 3-year RFFS probability for N3 stage was markedly lower than the rest (63%). The DFFS was significantly different between N stages (P-value < 0.001) and the 3-year DFFS probability decreased as N stage increased.
Conclusions
The 3-year OS and 3-year DFS rates in our study are comparable to those in peninsular Malaysia. The LFFS for T1-T3 stages is high. However, LFFS is low in T4 disease and DFFS is significantly low in N3 disease. Hence prospective studies are needed to determine if this group of patients may benefit from an intensified systemic treatment. Despite facing many challenges to access healthcare in Sabah, NPC patients in the state have a remarkably high compliance rate to radiotherapy treatment.
Clinical trial identification
NMRR ID-23-00055-E3N; RSCH ID-22-02599-GSk.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
613P - Differences in the interactions with pharmaceutical companies between medical oncologists and infectious diseases physicians
Presenter: Hui Ling Yeoh
Session: Poster Display
Resources:
Abstract
614P - The role of PD-L1 expression in prognosis of osteosarcoma patients: A systematic review and meta-analysis
Presenter: Alexander Purnomo
Session: Poster Display
Resources:
Abstract
615P - Pulmonary resectable metastases of osteosarcoma with apatinib and chemotherapy (PROACH): An open-label, single-arm phase II clinical trial
Presenter: Qiyuan Bao
Session: Poster Display
Resources:
Abstract
616P - Incidence of cardiotoxicity after high cumulative dose of anthracyclines in adult patients with advanced soft tissue sarcomas: A systematic review and meta-analysis
Presenter: Paula Franco
Session: Poster Display
Resources:
Abstract
617P - The risk of acute myeloid leukaemia in patients with Ewing's sarcoma and trend analysis: A SEER-based study 2000-2020
Presenter: Mohamed Abdalla
Session: Poster Display
Resources:
Abstract
618P - Adult renal Ewing’s sarcoma/primitive neuroectodermal tumor: A 20-year retrospective review of molecular histopathological profiles, and clinical outcomes
Presenter: Josh Thomas Georgy
Session: Poster Display
Resources:
Abstract
619P - Single-cell and bulk RNA-seq analyses decode the renal microenvironment induced by polystyrene microplastics in mice receiving high-fat diet
Presenter: Wangrui Liu
Session: Poster Display
Resources:
Abstract
620P - A unique circulating microRNA pairs signature serves as a superior tool for early diagnosis of pan-cancer
Presenter: Dongyu Li
Session: Poster Display
Resources:
Abstract
621P - Effective identification of primary liver cancer from cirrhosis or chronic hepatitis virus infection using eight methylated plasma DNA markers: Marker discovery, phase I pilot, and phase II clinical validation
Presenter: Tian Yang
Session: Poster Display
Resources:
Abstract
622P - A prognostic and immune infiltration analysis of CCL26 in pan-cancer
Presenter: Mengyue Li
Session: Poster Display
Resources:
Abstract